Global Smart Biopsy Devices Market Size (2024 - 2029)

The smart biopsy devices market is projected to experience growth over the forecast period, driven by the increasing prevalence of cancer globally. Despite the negative impact of the COVID-19 pandemic on diagnostic procedures, the market is expected to expand as the demand for biopsy procedures rises due to the growing cancer burden. However, challenges associated with core needle biopsy procedures may pose obstacles to market growth in the future.

Market Size of Global Smart Biopsy Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Smart Biopsy Devices Market Size
Study Period 2019 - 2029
Market Size (2024) USD 2.81 Billion
Market Size (2029) USD 3.62 Billion
CAGR (2024 - 2029) 5.23 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Smart Biopsy Devices Market Key Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Smart Biopsy Devices Market Analysis

The Global Smart Biopsy Devices Market size is estimated at USD 2.81 billion in 2024, and is expected to reach USD 3.62 billion by 2029, growing at a CAGR of 5.23% during the forecast period (2024-2029).

During the COVID 19 pandemic, the smart biopsy devices market was adversely affected. For instance, in January 2021, a research study published titled "Impact of COVID-19 on small biopsy diagnostic procedures and cancer resection surgeries in the North-West of Ireland" stated that there has been a significant impact on the provision of both diagnostic and therapeutic services in North-West of Ireland due to the COVID-19 pandemic. Similarly, another research study published in November 2020, titled "Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors" stated that the current impact of the COVID-19 pandemic on cancer care in the United States has resulted in decreases and delays in identifying new cancers and delivery of treatment. These problems, if unmitigated, will increase cancer morbidity and mortality for years to come. Similarly, another research study published in March 2021, titled "Impact of the COVID-19 pandemic on skin cancer diagnosis: A population-based study" stated that the COVID-19 pandemic has been unprecedented and has led to drastic reductions in non-urgent medical visits. A precipitous drop in total skin biopsies (15% of expected), biopsies for keratinocyte carcinoma (KC) (18%) and melanoma (27%) was seen with the onset of COVID-19 cases. Claims diagnoses were of high specificity for KC (99%), and for melanoma (98%), though sensitivity was less (61% and 28% respectively). In adjusted analysis, the elderly (80+ years), females and residents of certain regions were less likely to be biopsied during the pandemic. Subsequently, there were substantial improvements in biopsy rates over 10 weeks. Hence, in the short term the market was negatively impacted however, post pandemic the market is likely to grow.

The market is increasing due to increasing prevalence of cancer. The Globocan 2020 report published by Global Cancer Observatory, which estimated the incidence and mortality of 36 cancer in 185 countries, globally, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020 and about 9,958,133 people died due to cancer, all over the world. Further, as per the same source, the number of new cancer cases are expected to reach 24,044,406 by 2030, which shows an increasing prevalence of cancer around the globe. High prevalence of cancer will require treatment and will increase the growth of the market. Similarly, as per the GLOBOCAN 2020, in 2020, there were 19.3 million estimated number of new cancer cases worldwide, and the number is estimated to reach 30.2 million by the year 2040. Thus, the anticipated increase in burden of cancer is a major factor contributing to the rising demand for biopsy, thereby boosting the market growth.

However, the clinical issues with core needle biopsy will hinder the market growth in upcoming future.

Smart Biopsy Devices Industry Segmentation

As per the scope of this report the smart biopsy devices are various pieces of equipment interconnected with each other that are used for the surgical extraction of tissues from an organ. The Smart Biopsy Devices Market is segmented by Application (Breast Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, and Others) End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Application
Breast Cancer
Liver Cancer
Skin Cancer
Prostate Cancer
Others
End User
Hospitals
Academic and Research Institutes
Diagnostic and Imaging Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Smart Biopsy Devices Market Size Summary

The smart biopsy devices market is poised for growth, driven by the increasing prevalence of cancer globally. The market experienced a temporary setback during the COVID-19 pandemic, which disrupted diagnostic and therapeutic services, leading to delays in cancer diagnosis and treatment. However, the demand for smart biopsy devices is expected to rise as the burden of cancer continues to grow, necessitating more frequent and advanced diagnostic procedures. The high incidence of breast cancer, in particular, is a significant factor propelling the market, as these devices are crucial for early detection and diagnosis. The introduction of innovative products, such as Izi Medical Products' Quick-Core Auto Biopsy System, further supports market expansion by enhancing biopsy procedures.

North America is anticipated to lead the smart biopsy devices market, supported by substantial funding for cancer research and development, a robust presence of key industry players, and proactive initiatives by major companies. The region's focus on advancing digital breast cancer screening methods and increasing mammography procedures contributes to the market's growth. Additionally, partnerships and regulatory approvals, such as Guardant Health's collaboration with Epic and the approval of Guardant360 CDx in Japan, highlight the ongoing advancements and strategic moves within the industry. These factors collectively underscore the market's potential for continued expansion in the coming years.

Explore More

Global Smart Biopsy Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Preference for Minimally Invasive Biopsy Procedure

      2. 1.2.2 Increasing Prevalence of Cancer

    3. 1.3 Market Restraints

      1. 1.3.1 Clinical Issues With Core Needle Biopsy

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Application

      1. 2.1.1 Breast Cancer

      2. 2.1.2 Liver Cancer

      3. 2.1.3 Skin Cancer

      4. 2.1.4 Prostate Cancer

      5. 2.1.5 Others

    2. 2.2 End User

      1. 2.2.1 Hospitals

      2. 2.2.2 Academic and Research Institutes

      3. 2.2.3 Diagnostic and Imaging Centers

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East & Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East & Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Smart Biopsy Devices Market Size FAQs

The Global Smart Biopsy Devices Market size is expected to reach USD 2.81 billion in 2024 and grow at a CAGR of 5.23% to reach USD 3.62 billion by 2029.

In 2024, the Global Smart Biopsy Devices Market size is expected to reach USD 2.81 billion.

Smart Biopsy Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)